[Higher cradiovascular risc with hypomagnesemia].

V. Brandenburg

DOI: https://doi.org/10.1055/s-0042-101839

2016-03-01

Abstract:Magnesium reguliert Entzundungsprozesse und die Endothelfunktion, beeinflusst durch elektrische Effekte aber auch den Herzmuskel. In bestimmten Risikogruppen, z. B. bei herzinsuffizienten Patienten, hat etwa jeder Zweite einen Magnesium-Mangel. Das kann unter anderem mit einer erhohten koronaren Sterblichkeit einhergehen.

What problem does this paper attempt to address?

[Magnesium in critical care and anesthesiology]

J Montupil,J L Vincent

Abstract:Magnesium (Mg) is an essential ion for life and is involved in many important biological processes. Mg deficiency may have serious consequences and has been implicated in many diseases. Assessment of Mg status is difficult because Mg is essentially intracellular and there is no simple, rapid and accurate laboratory test to determine total body Mg. New, non-invasive techniques are being developed that could be used in the near future. Mg therapy is clearly indicated in "torsade de pointes" and preeclampsia. Mg therapy is not recommended in the treatment of acute myocardial infarction, stroke or non-severe acute asthma. Nevertheless, Mg administration may be useful to reduce cerebral ischemic events after aneurysmal subarachnoid hemorrhage or in the treatment of severe acute asthma, specifically in children. Finally, the potential post-operative analgesic effect of Mg is still debated and results from new, larger clinical trials may help clarify this issue. This article reviews physiological functions and pharmacology of Mg status as well as the causes, clinical manifestations, and treatment of Mg deficiency. The possible analgesic effects of Mg in the postoperative period are also reviewed.
Magnesium: Pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage

Jason J. Chang,Rocco Armonda,Nitin Goyal,Adam S. Arthur,AdamS Arthur,JasonJ Chang

DOI: https://doi.org/10.4103/1673-5374.251189

2019-01-01

Neural Regeneration Research

Abstract:Intracerebral hemorrhage (ICH) remains the second-most common form of stroke with high morbidity and mortality. ICH can be divided into two pathophysiological stages: an acute primary phase, including hematoma volume expansion, and a subacute secondary phase consisting of blood-brain barrier disruption and perihematomal edema expansion. To date, all major trials for ICH have targeted the primary phase with therapies designed to reduce hematoma expansion through blood pressure control, surgical evacuation, and hemostasis. However, none of these trials has resulted in improved clinical outcomes. Magnesium is a ubiquitous element that also plays roles in vasodilation, hemostasis, and blood-brain barrier preservation. Animal models have highlighted potential therapeutic roles for magnesium in neurological diseases specifically targeting these pathophysiological mechanisms. Retrospective studies have also demonstrated inverse associations between admission magnesium levels and hematoma volume, hematoma expansion, and clinical outcome in patients with ICH. These associations, coupled with the multifactorial role of magnesium that targets both primary and secondary phases of ICH, suggest that magnesium may be a viable target of study in future ICH studies.

neurosciences,cell biology
Associations Between Dietary Magnesium Intake and Hypertension, Diabetes, and Hyperlipidemia

Mengying Han,Yixin Zhang,Jiaxin Fang,Ming Sun,Qitong Liu,Zhaoyu Ma,Daibao Hu,Xiaoyu Gong,Yang Liu,Lina Jin,Zuyun Liu,Yanan Ma

DOI: https://doi.org/10.1038/s41440-023-01439-z

2024-01-01

Hypertension Research

Abstract:Hypertension, diabetes, and hyperlipidemia significantly impact chronic diseases and mortality. Magnesium is an essential nutrient for maintaining critical physiological functions, and magnesium deficiency is often associated with adverse health outcomes. In a cross-sectional study of US adults, we aimed to explore dietary magnesium intake and its association with the prevalence of hypertension, diabetes, and hyperlipidemia in US adults over 20 years of age in NHANES 2007–2018. We obtained data on 24,171 samples of hypertension, 9950 samples of diabetes, and 12,149 samples of hyperlipidemia. We used multivariable logistic regression models adjusted for multiple sociodemographic, anthropometric, and lifestyle factors, with participants subdivided into five groups based on quintiles of daily dietary magnesium. After adjusting for the major lifestyle and dietary variables, an independent and significant inverse relationship between dietary magnesium and hypertension, diabetes, and hyperlipidemia was observed. Compared with the lowest quintile of magnesium intake, the prevalence of hypertension, diabetes, and hyperlipidemia was significantly reduced in the highest magnesium quintile. The OR of hypertension in the highest quintile was 0.66 (95% CI: 0.51–0.87; P trend < 0.001), the OR of diabetes was 0.56 (95% CI: 0.39–0.81; P trend < 0.001), and the OR of hyperlipidemia was 0.68 (95% confidence interval: 0.53–0.86; P trend = 0.007). In the subgroup analysis, most of the inverse relationships persisted. Our findings highlight the potential of magnesium-rich foods to prevent hypertension, diabetes, and hyperlipidemia in US adults. This article summarizes and discuss recent findings on: 1) A high dietary magnesium intake was associated with a lower prevalence of hypertension; 2) An inverse relationship between dietary magnesium with diabetes hyperlipidemia; 3) Monitoring and management of magnesium was important.
Effects of serum magnesium level on mortality in maintenance hemodialysis patients

李清,姚曦,陈江华,张萍

DOI: https://doi.org/10.3760/cma.j.cn441217-20200105-00144

2020-01-01

Abstract:Objective:To investigate the effects of serum magnesium level on all-cause mortality and cardiovascular and cerebrovascular diseases mortality in maintenance hemodialysis (MHD) patients.Methods:Clinical data of MHD patients in Shaoxing People's Hospital from June 1, 2016 to June 30, 2018 were collected retrospectively. The patients were divided into low magnesium group (serum magnesium≤0.96 mmol/L) , medium magnesium group (serum magnesium 0.97-1.07 mmol/L) and high magnesium group (serum magnesium≥1.08 mmol/L) according to the tertile of mean serum magnesium level. The differences of clinical data and laboratory results were compared among the three groups. Kaplan-Meier method was used to draw the survival curves, and log-rank test was used to compare the survival rate differences. Multivariate Cox regression was used to analyze the relationship between serum magnesium and all-cause mortality and cardiovascular and cerebrovascular diseases mortality in MHD patients. Results:A total of 332 patients [194 males (58.4%)] were included in this study, with a median age of 63(51, 72) years and a median follow-up time of 36(20, 45) months. Kaplan-Meier survival analysis showed that the all-cause survival rate and cardiovascular and cerebrovascular diseases survival rate in the low magnesium group were lower than those in the medium magnesium group and the high magnesium group (Log-rank χ2=36.286, P<0.001; Log-rank χ2=20.145, P<0.001; respectively). After adjusting for multiple confounding factors, the results of multivariate Cox regression analysis suggested that low serum magnesium was an independent risk factor for all-cause death and cardiovascular and cerebrovascular diseases death in MHD patients. The risk of all-cause death and cardiovascular and cerebrovascular diseases death in the low magnesium group were significantly higher than those in the high magnesium group ( HR=2.925, 95% CI 1.352-6.330, P=0.006; HR=3.821, 95% CI 1.394-10.473, P=0.009; respectively). Conclusions:Hypomagnesemia may be an independent risk factor for all-cause death and cardiovascular and cerebrovascular diseases death in MHD patients. Low serum magnesium level increases the risk of all-cause death and cardiovascular and cerebrovascular diseases in MHD patients.
Serum magnesium level and hematoma expansion in patients with intracerebral hemorrhage

Mostafa Jafari,Mario Di Napoli,Simona Lattanzi,Stephan A Mayer,Salam Bachour,Eric M Bershad,Rahul Damani,Yvonne H Datta,Afshin A Divani,Stephan A. Mayer,Eric M. Bershad,Yvonne H. Datta,Afshin A. Divani

DOI: https://doi.org/10.1016/j.jns.2019.01.027

IF: 4.4

2019-03-01

Journal of the Neurological Sciences

Abstract:Spontaneous intracerebral hemorrhage (ICH) is a devastating subtype of stroke that results in significant rates of mortality and morbidities. The initial hematoma volume, hematoma expansion (HE), blood pressure (BP), and coagulopathy are considered strong predictors of clinical outcomes and mortality. Low serum magnesium (Mg++) levels have been shown to be associated with larger initial hematoma and greater HE. Coagulopathy, platelet dysfunction, high BP, and increased inflammatory response might form the mechanistic link between low serum Mg++ levels, larger hematoma size and greater HE. However, randomized clinical trials administering intravenous Mg++ have shown no benefit over placebo in ICH patients. The confounding effect of hypocalcemia and a delay in Mg++ trafficking across the blood-brain barrier might explain the futile results for intravenous Mg++ therapy. In the current review, we will discuss the evidence regarding the possible role of low serum Mg++ level on HE in acute ICH.

neurosciences,clinical neurology
Multiple sulphatase deficiency and carotenaemia

A. Homma,H. Ikeda,R. Ishii,K. Sukegawa,K. Hayasaka

DOI: https://doi.org/10.1007/BF01799355

IF: 4.7501

1996-01-01

Journal of Inherited Metabolic Disease

Abstract:
Magnesium Biology

Jana L Kröse,Jeroen H F de Baaij

DOI: https://doi.org/10.1093/ndt/gfae134

IF: 7.1857

2024-06-13

Nephrology Dialysis Transplantation

Abstract:Abstract Magnesium (Mg2+) is essential for energy metabolism, muscle contraction, and neurotransmission. As part of the Mg-ATP complex, it is involved in over 600 enzymatic reactions. Serum Mg2+ levels are tightly regulated between 0.7 mmol/L and 1.1 mmol/L by interplay of intestinal absorption and renal excretion. In the small intestine, Mg2+ is absorbed paracellularly via claudin-2, and -12. In the colon, transcellular absorption of Mg2+ is facilitated by TRPM6/7 and CNNM4. In the kidney, the proximal tubule reabsorbs only 20% of the filtered Mg2+. The majority of the filtered Mg2+ is reabsorbed in the thick ascending limb (TAL), where the lumen-positive transepithelial voltage drives paracellular transport via claudin-16/-19. Fine-tuning of Mg2+ reabsorption is achieved in the distal convoluted tubule (DCT). Here, TRPM6/7 tetramers facilitate apical Mg2+ uptake, which is hormonally regulated by insulin and EGF. Basolateral Mg2+ extrusion is Na+ dependent and achieved by CNNM2 and/or SLC41A3. Hypomagnesemia (serum Mg2+ < 0.7 mmol/L) develops when intestinal and/or renal Mg2+ (re)absorption is disturbed. Common causes include alcoholism, type 2 diabetes mellitus, and the use of pharmacological drugs, such as proton-pump inhibitors (PPIs), calcineurin inhibitors (CNIs) and thiazide diuretics. Over the last decade, research on rare genetic and acquired Mg2+ disorders have identified Mg2+ channel and transporter activity, DCT length, mitochondrial function, and autoimmunity as mechanisms explaining hypomagnesemia. Classically, treatment of hypomagnesemia depended on oral or intravenous Mg2+ supplementation. Recently, prebiotic dietary fibers and SGLT2 inhibitors have been proposed as promising new therapeutic pathways to treat hypomagnesemia.

urology & nephrology,transplantation
The prognostic impact of magnesium in acute heart failure is different according to the presence of diabetes mellitus

Catarina Cidade-Rodrigues,Filipe M. Cunha,Catarina Elias,Marta Carreira,Isaac Barroso,Paulo Bettencourt,Patrícia Lourenço

DOI: https://doi.org/10.1097/j.pbj.0000000000000197

2022-12-18

Porto Biomedical Journal

Abstract:Heart failure (HF) is a common condition associated with elevated morbidity and mortality. 1 Hypomagnesemia is a frequent electrolyte abnormality in patients with HF and has been linked to premature ventricular contractions and potentially life-threatening arrhythmias. 2,3
Magnesium and Human Health: Perspectives and Research Directions

Abdullah M. Al Alawi,Sandawana William Majoni,Henrik Falhammar

DOI: https://doi.org/10.1155/2018/9041694

2018-01-01

International Journal of Endocrinology

Abstract:Magnesium is the fourth most abundant cation in the body. It has several functions in the human body including its role as a cofactor for more than 300 enzymatic reactions. Several studies have shown that hypomagnesemia is a common electrolyte derangement in clinical setting especially in patients admitted to intensive care unit where it has been found to be associated with increase mortality and hospital stay. Hypomagnesemia can be caused by a wide range of inherited and acquired diseases. It can also be a side effect of several medications. Many studies have reported that reduced levels of magnesium are associated with a wide range of chronic diseases. Magnesium can play important therapeutic and preventive role in several conditions such as diabetes, osteoporosis, bronchial asthma, preeclampsia, migraine, and cardiovascular diseases. This review is aimed at comprehensively collating the current available published evidence and clinical correlates of magnesium disorders.

endocrinology & metabolism
Genetics of Magnesium Disorders

Heng Li,Shiren Sun,Jianghua Chen,Goushuang Xu,Hanmin Wang,Qi Qian

DOI: https://doi.org/10.1159/000477730

2017-01-01

Kidney Diseases

Abstract:Background: Magnesium (Mg2+), the second most abundant cation in the cell, is woven into a multitude of cellular functions. Dysmagnesemia is associated with multiple diseases and, when severe, can be life-threatening. Summary: This review discusses Mg2+ homeostasis and function with specific focus on renal Mg2+ handling. Intrarenal channels and transporters related to Mg2+ absorption are discussed. Unraveling the rare genetic diseases with manifestations of dysmagnesemia has greatly increased our understanding of the complex and intricate regulatory network in the kidney, specifically, functions of tight junction proteins including claudin-14, -16, -19, and -10; apical ion channels including: TRPM6, K(v)1.1, and ROMK; small regulatory proteins including AC3 and ANK3; and basolateral proteins including EGF receptor, gamma-subunit (FXYD2) of Na-K-ATPase, K(ir)4.1, CaSR, CNNM2, and SLC41A. Although our understanding of Mg2+ handling of the kidney has expanded considerably in the last two decades, many questions remain. Future studies are needed to elucidate a multitude of unknown aspects of Mg2+ handling in the kidney. Key Message: Understanding rare and genetic diseases of Mg2+ dysregulation has expanded our knowledge and furthers the development of strategies for preventing and managing dysmagnesemia. (c) 2017 S. Karger AG, Basel
Magnesium and Vascular Calcification in Chronic Kidney Disease: Current Insights

Shari J Zaslow,Gustavo H Oliveira-Paula,Wei Chen

DOI: https://doi.org/10.3390/ijms25021155

2024-01-18

Abstract:Magnesium (Mg) plays crucial roles in multiple essential biological processes. As the kidneys are the primary organ responsible for maintaining the blood concentration of Mg, people with chronic kidney disease (CKD) may develop disturbances in Mg. While both hyper- and hypomagnesemia may lead to adverse effects, the consequences associated with hypomagnesemia are often more severe and lasting. Importantly, observational studies have shown that CKD patients with hypomagnesemia have greater vascular calcification. Vascular calcification is accelerated and contributes to a high mortality rate in the CKD population. Both in vitro and animal studies have demonstrated that Mg protects against vascular calcification via several potential mechanisms, such as inhibiting the formation of both hydroxyapatite and pathogenic calciprotein particles as well as limiting osteogenic differentiation, a process in which vascular smooth muscle cells in the media layer of the arteries transform into bone-like cells. These preclinical findings have led to several important clinical trials that have investigated the effects of Mg supplementation on vascular calcification in people with CKD. Interestingly, two major clinical studies produced contradictory findings, resulting in a state of equipoise. This narrative review provides an overview of our current knowledge in the renal handling of Mg in health and CKD and the underlying mechanisms by which Mg may protect against vascular calcification. Lastly, we evaluate the strength of evidence from clinical studies on the efficacy of Mg supplementation and discuss future research directions.
Learning Weights in Discrimination Functions Using a priori Constraints

N. Krüger

DOI: https://doi.org/10.1007/978-3-642-79980-8_13

1995-09-13

Abstract:
Prevalence of Dysmagnesemia among Patients with Diabetes Mellitus and the Associated Health Outcomes: A Cross-Sectional Study

Salwa Al Harasi,Juhaina Salim Al-Maqbali,Henrik Falhammar,Ali Al-Mamari,Abdullah Al Futisi,Ahmed Al-Farqani,Suneel Kumar,Alaa Osman,Sulaiman Al Riyami,Nafila Al Riyami,Qatiba Al Farai,Hiba Al Alawi,Abdullah M. Al Alawi

DOI: https://doi.org/10.3390/biomedicines12051068

IF: 4.757

2024-05-12

Biomedicines

Abstract:Introduction: Magnesium is a vital intracellular cation crucial for over 320 enzymatic reactions related to energy metabolism, musculoskeletal function, and nucleic acid synthesis and plays a pivotal role in human physiology. This study aimed to explore the prevalence of dysmagnesemia in patients with diabetes mellitus and evaluate its correlations with glycemic control, medication use, and diabetic complications. Methods: A cross-sectional study was conducted at Sultan Qaboos University Hospital, including 316 patients aged 18 years or older with diabetes mellitus. Data included demographics, medical history, medications, and biochemical parameters. Serum total magnesium concentrations were measured, and dysmagnesemia was defined as magnesium ≤ 0.69 mmol/L for hypomagnesemia and ≥1.01 mmol/L for hypermagnesemia. Results: The prevalence of hypomagnesemia in patients with diabetes was 17.1% (95% CI: 13.3–21.7%), and hypermagnesemia was 4.1% (95% CI: 2.4–7.0%). Females were significantly overrepresented in the hypomagnesemia group, while the hypermagnesemia group showed a higher prevalence of hypertension, retinopathy, an increased albumin/creatinine ratio, chronic kidney disease (CKD), elevated creatinine levels, and a lower adjusted calcium concentration. The multinominal logistic regression exhibited that the female sex and higher serum-adjusted calcium were independent risk factors of hypomagnesemia. In contrast, the presence of hypertension, higher levels of albumin/creatinine ratio, and stage 5 CKD were independent risk factors of hypermagnesemia. Conclusions: Hypomagnesemia was common among patients with diabetes mellitus; however, hypermagnesemia was associated with microvascular complications.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Magnesium homeostasis in critically ill patients

E Ryzen

Abstract:Magnesium (Mg) deficiency is a common finding in critically ill patients. Mg deficiency results primarily from gastrointestinal or urinary Mg losses, but malnutrition and decreased dietary Mg intake may hasten the development of Mg depletion. In our medical intensive-care unit, we have found hypomagnesemia in 65% of patients with normal serum creatinine concentrations. The prevalence of normomagnesemic Mg deficiency in critically ill patients may be even higher and may contribute to the pathogenesis of hypocalcemia, cardiac arrhythmias and other symptoms of Mg deficiency.
Clinical intervention studies on magnesium in myocardial infarction

H S Rasmussen

Abstract:Patients with acute myocardial infarction (AMI) display a significant decrease in serum magnesium concentrations (S-Mg,c) during the initial 48 h after infarction. This decrease is not due to an increased renal magnesium loss, neither is it a dilution phenomenon. Consequently, a migration of Mg from the extracellular to intracellular space might take place, which probably is due to a catecholamine-induced increased lipolysis, forming insoluble intracellular Mg soaps. As the Mg ion is crucial in maintaining the electrical stability of the myocardium, we found it rational to avoid this postinfarctional hypomagnesemia by administration of Mg. In a double-blind, placebo-controlled trial, 130 patients with AMI were randomly allocated to receive a total of 62 mmol magnesium chloride or placebo intravenously during the initial 48 h in hospital. Mg treatment was associated with a reduction in the acute mortality from 19% in the placebo group to 7% in the Mg group (p = 0.045). This reduction was primarily due to a reduction in the number of deaths due to cardiogenic shock. The incidence of arrhythmias needing treatment was more than halved (from 47% in the placebo group to 21% in the Mg group; p = 0.003), primarily due to a reduction in the incidence of supraventricular tachyarrhythmias. Finally, Mg treatment significantly influenced the AMI diagnosis, as only 56/136 Mg-treated patients (41%) versus 74/137 placebo-treated patients (54%) developed an infarction (p less than 0.05). The mechanisms behind this beneficial effect of the Mg infusions are extensively discussed in this paper. Our results have now been confirmed by three other different groups with similar protocols. On the basis of this, we conclude that immediately instituted intravenous Mg treatment should be adopted as part of the routine treatment for patients presenting with AMI.
In Situ Identification by Fluorescently Labeled Oligonucleotide Probes of Morphologically Similar, Closely Related Ciliate Species

G. Petroni,G. Rosati,C. Vannini,L. Modeo,F. Dini,F. Verni

DOI: https://doi.org/10.1007/s00248-002-2016-x

IF: 4.192

2003-02-01

Microbial Ecology

Abstract:
Serum magnesium, mortality and disease progression in chronic kidney disease

Rami Azem,Remy Daou,Elias Bassil,Eva Maria Anvari,Jonathan J. Taliercio,Susana Arrigain,Jesse D. Schold,Tushar Vachharajani,Joseph Nally,Georges N. Na khoul

DOI: https://doi.org/10.1186/s12882-020-1713-3

2020-02-12

BMC Nephrology

Abstract:Abstract Introduction Magnesium disorders are commonly encountered in chronic kidney disease (CKD) and are typically a consequence of decreased kidney function or frequently prescribed medications such as diuretics and proton pump inhibitors. While hypomagnesemia has been linked with increased mortality, the association between elevated magnesium levels and mortality is not clearly defined. Additionally, associations between magnesium disorders, type of death, and CKD progression have not been reported. Therefore, we studied the associations between magnesium levels, CKD progression, mortality, and cause specific deaths in patients with CKD. Methods Using the Cleveland Clinic CKD registry, we identified 10,568 patients with estimated Glomerular Filtration Rate (eGFR) between 15 and 59 ml/min/1.73 m 2 in this range for a minimum of 3 months with a measured magnesium level. We categorized subjects into 3 groups based on these magnesium levels (≤ 1.7, 1.7–2.6 and > 2.6 mg/dl) and applied cox regression modeling and competing risk models to identify associations with overall and cause-specific mortality. We also evaluated the association between magnesium level and slope of eGFR using mixed models. Results During a median follow-up of 3.7 years, 4656 (44%) patients died. After adjusting for relevant covariates, a magnesium level 2.6 mg/dl (vs. 1.7–2.6 mg/dl) was associated with a higher risk of all-cause death only (HR = 1.23, 95% CI: 1.03, 1.48). We found similar results when evaluating magnesium as a continuous measure. There were no significant differences in the slope of eGFR across all three magnesium groups ( p = 0.10). Conclusions In patients with CKD stage 3 and 4, hypomagnesemia was associated with higher all-cause and non-cardiovascular non-malignancy mortality. Hypermagnesemia was associated with higher all-cause mortality. Neither hypo nor hypermagnesemia were associated with an increased risk of CKD progression.

urology & nephrology
Magnesium therapy of cardiac arrhythmias in critical-care medicine

L T Iseri,B J Allen,M A Brodsky

Abstract:A common complication of critically ill patients is cardiac tachyarrhythmia. The role played by magnesium is not well appreciated. Well-documented cases indicated that magnesium may be effective in controlling the rhythm when conventional methods fail. The following tachyarrhythmias respond favorably to magnesium: (1) intractable ventricular tachycardia and fibrillation, whether hypo- or normomagnesemic, (2) torsades de pointes, (3) digitalis-toxic ventricular tachyarrhythmia, (4) multifocal atrial tachycardia and (5) hypomagnesemic atrial tachyarrhythmia. It is recommended that 10-15 ml of 20% MgSO4 be infused over 1 min, followed by 500 ml of 2% MgSO4 over 5 h. A second 500 ml over 10 h may be necessary. Renal failure, disappearance of deep tendon reflex, rise in serum Mg above 5 mEq/l, drop in systolic blood pressure below 80 or drop in pulse below 60 contraindicate the continued use of magnesium. If serum potassium is at or falls below 4.0 mEq/l, 20-40 mEq/l KCl should be added. Magnesium deficiency can be confirmed by a low serum level or by a greater than 50% retention of administered magnesium. The causes of magnesium deficiency can be remembered under 10 DS: (1) Diarrhea and gastrointestinal losses, (2) Diuretics and renal losses, (3) Diabetes and endocrine causes, (4) Dietary lack, (5) Diverted to free fatty acids, (6) Drugs such as cisplatin, (7) Drinking alcohol to excess, (8) Delivery with toxemia, (9) Decompensated heart, lungs or liver and (10) Denuded skin, such as burns.
Protective Effects Of Magnesium Against Ischaemia-Reperfusion Injury Through Inhibition Of P-Selectin In Rats

Shu-Qin Ying,Lu Fang,Mei-Xiang Xiang,Geng Xu,Jiang Shan,Jian-An Wang

DOI: https://doi.org/10.1111/j.1440-1681.2007.04697.x

2007-01-01

Clinical and Experimental Pharmacology and Physiology

Abstract:1. The leucocyte-mediated inflammatory response plays a pivotal role in ischaemia-reperfusion injury. P-Selectin and CD11b are important mediators for the recruitment of leucocytes into the endothelium. However, the time-course of changes in P-selectin and CD11b expression during reperfusion is not defined. Magnesium has been shown to have a protective role in reperfusion injury, but the mechanism of its action is not yet clear.2. In the present study, 90 male Sprague-Dawley rats were randomized into three groups, namely a sham-operated group, an IR group (subjected to 45 min of coronary occlusion followed by reperfusion for up to 6 h) and an MgSO4-treated group, which received an infusion of MgSO4 starting 30 min before occlusion and continuing until the onset of reperfusion. The expression of P-selectin on platelets and CD11b on leucocytes, endothelial P-selectin on cardiac microvessels and P-selectin mRNA in myocardial tissue were measured by flow cytometry, immunohistochemistry and reverse transcription-polymerase chain reaction, respectively, at different time points during reperfusion. The degree of myocardial necrosis and arrhythmia was assessed.3. The present study shows that P-selectin expression on platelets and cardiac microvessels, P-selectin mRNA in myocardial tissue and CD11b expression on leucocytes in the IR group were significantly upregulated compared with the sham-operated group in a time-dependent manner during reperfusion. Treatment with MgSO4 attenuated the upregulation of P-selectin expression, in addition to inhibiting myocardial necrosis and arrhythmia, but had no effect on CD11b expression on leucocytes.4. These results suggest that the expression of P-selectin and CD11b is upregulated after reperfusion and magnesium pretreatment plays a cardioprotective role in ischaemia-reperfusion injury, possibly by inhibiting the upregulation of P-selectin expression.
An investigation of hypomagnesemia among ambulatory urban African Americans

C H Fox,D Ramsoomair,M C Mahoney,C Carter,B Young,R Graham

Abstract:Background: Magnesium represents the fourth most abundant cation in the body and plays an integral role in intracellular metabolism. Although magnesium deficiency states have been associated with a variety of medical conditions, the prevalence of hypomagnesemia has not been well studied, particularly in ambulatory settings. Methods: We performed a period prevalence study using 120 patients seen for routine medical care at an urban family medicine center. Chart reviews were completed for these subjects. We used univariate and multivariate analyses to correlate magnesium levels with demographic and clinical factors. Results: There was a 20% overall prevalence of hypomagnesemia among this predominantly female, African American population. The prevalence of hypomagnesemia was greatest among patients with a history of alcoholism (odds ratio [OR] = 6.00; 95% confidence interval [CI], 1.41-26.1) and among those having 1 or more of the following medical conditions: diabetes, hyperlipidemia, hypertension, renal disease, and asthma (OR = 4.69; 95% CI, 1.37-17.65). Conclusions: The prevalence of hypomagnesemia among patients from this urban minority community exceeds that reported in previous studies of the general population. This may be reflective of greater comorbidity, diminished nutritional status, or poorer overall health among patients from this community. The association between hyperlipidemia and magnesium deficiency warrants further investigation.

[Higher cradiovascular risc with hypomagnesemia].

[Magnesium in critical care and anesthesiology]

Magnesium: Pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage

Associations Between Dietary Magnesium Intake and Hypertension, Diabetes, and Hyperlipidemia

Effects of serum magnesium level on mortality in maintenance hemodialysis patients

Serum magnesium level and hematoma expansion in patients with intracerebral hemorrhage

Multiple sulphatase deficiency and carotenaemia

Magnesium Biology

The prognostic impact of magnesium in acute heart failure is different according to the presence of diabetes mellitus

Magnesium and Human Health: Perspectives and Research Directions

Genetics of Magnesium Disorders

Magnesium and Vascular Calcification in Chronic Kidney Disease: Current Insights

Learning Weights in Discrimination Functions Using a priori Constraints

Prevalence of Dysmagnesemia among Patients with Diabetes Mellitus and the Associated Health Outcomes: A Cross-Sectional Study

Magnesium homeostasis in critically ill patients

Clinical intervention studies on magnesium in myocardial infarction

In Situ Identification by Fluorescently Labeled Oligonucleotide Probes of Morphologically Similar, Closely Related Ciliate Species

Serum magnesium, mortality and disease progression in chronic kidney disease

Magnesium therapy of cardiac arrhythmias in critical-care medicine

Protective Effects Of Magnesium Against Ischaemia-Reperfusion Injury Through Inhibition Of P-Selectin In Rats

An investigation of hypomagnesemia among ambulatory urban African Americans